Pricing
  1. US-listed companies
  2. Panbela Therapeutics, Inc.
  3. Raw

Panbela Therapeutics, Inc.【PBLA】

Market cap
$63.36K
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net loss247,380-212,021-107,044-5-5-1035-6-5-10-35-25
Gain on sale of intellectual property-----------0
Stock-based compensation600600-112111111
Non-cash interest expense----0122---0
Income tax receivable-------000-0-00
Prepaid expenses and other current assets---0-00-00-0-00-0
Deposits held for clinical trial costs-----------6
Accounts payable-10,558-24,147-3,654-1-000-1127
Accrued liabilities-17,56541,158-29,377-1000011-2
Net cash used in operating activities37,113-35,390-11,453---3-2-3-4-7-15-25
Proceeds from sale of intellectual property-----------0
Investment in IPR&D----------1-
Cash acquired in merger----------0-
Net cash used in investing activities19,123-5,115124,720-------1-10
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $2,075 and $727 respectively--------9---
Proceeds from induced exercise of warrants, net of costs of $359---000--010-
Payments made on notes payable-------01--2
Cash paid for fractional shares-----------0
Net cash provided by financing activities6,851-11,611-8,317--3441010526
Effect of exchange rate changes on cash-----------0-
Net change in cash--------73-111
Cash paid during period for interest-----0000000
Fair value of common stock, stock options and stock warrants issued as consideration for asset acquisition----------10-
Adjustment for the value offered to induce warrant exercise-----------9,140